A randomized controlled trial to evaluate genotyping and therapeutic drug monitoring vs. only therapeutic drug monitoring as a strategy for risk minimization in epileptic patients on carbamazepine therapy
Objective: Carbamazepine (CBZ) is a widely prescribed antiepileptic drug for the treatment of focal seizures. CBZ gets metabolized by cytochrome enzymes mainly CYP3A5. It is difficult to predict clinically whether a patient is likely to suffer from CBZ toxicity. Hence, we planned to evaluate the use...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Atatürk University
2025-04-01
|
| Series: | Recent Trends in Pharmacology |
| Subjects: | |
| Online Access: | https://dergipark.org.tr/en/download/article-file/4496181 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850204331693834240 |
|---|---|
| author | Hina Khimsuriya Sanchita Ambre Swati More Vinayak A Mahesh Belhekar |
| author_facet | Hina Khimsuriya Sanchita Ambre Swati More Vinayak A Mahesh Belhekar |
| author_sort | Hina Khimsuriya |
| collection | DOAJ |
| description | Objective: Carbamazepine (CBZ) is a widely prescribed antiepileptic drug for the treatment of focal seizures. CBZ gets metabolized by cytochrome enzymes mainly CYP3A5. It is difficult to predict clinically whether a patient is likely to suffer from CBZ toxicity. Hence, we planned to evaluate the use of genotyping and therapeutic drug monitoring (TDM) vs. only TDM in epileptic patients on CBZ as a strategy for risk minimization. Methods: This double-blind, randomized controlled trial included 60 epileptic patients taking carbamazepine, divided into two equal groups. One group’s carbamazepine dosing was guided by genotyping, while the other group’s doses were based solely on clinical judgment.Results: A total of 60 patients were enrolled in the study, in two arms, group A (genotyping and TDM both) and Group B (only TDM), each arm comprising 30 patients. Among the CYP3A5 metabolizer group, the frequency of expressors and non-expressors was (57%) and (43%), respectively. During follow-up visits, at one month, three cases of adverse drug reactions (ADRs) were reported. ADR count decreased to two cases during the three-month follow-up and further reduced to only one case of ADR at the 12-month assessment. It was found that there is no statistically significant association between CYP3A5 metabolizer and ADR occurrence.Conclusion: Adding genotyping to TDM did not significantly reduce the risk of carbamazepine toxicity. However, genotyping may still be useful for patients who exhibit symptoms of toxicity. |
| format | Article |
| id | doaj-art-3822da2758b34acda37a77d4e50f921b |
| institution | OA Journals |
| issn | 2980-194X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Atatürk University |
| record_format | Article |
| series | Recent Trends in Pharmacology |
| spelling | doaj-art-3822da2758b34acda37a77d4e50f921b2025-08-20T02:11:18ZengAtatürk UniversityRecent Trends in Pharmacology2980-194X2025-04-0131273510.62425/rtpharma.161412755A randomized controlled trial to evaluate genotyping and therapeutic drug monitoring vs. only therapeutic drug monitoring as a strategy for risk minimization in epileptic patients on carbamazepine therapyHina Khimsuriya0https://orcid.org/0009-0004-1528-7064Sanchita Ambre1https://orcid.org/0009-0007-3847-7989Swati More2https://orcid.org/0009-0009-6784-2011Vinayak A3https://orcid.org/0009-0002-8832-348XMahesh Belhekar4https://orcid.org/0009-0005-5774-0565Seth G.S. Medical College and K.E.M. HospitalSeth G.S. Medical College and K.E.M. HospitalSeth G.S. Medical College and K.E.M. HospitalSeth G.S. Medical College and K.E.M. HospitalSeth G.S. Medical College and K.E.M. HospitalObjective: Carbamazepine (CBZ) is a widely prescribed antiepileptic drug for the treatment of focal seizures. CBZ gets metabolized by cytochrome enzymes mainly CYP3A5. It is difficult to predict clinically whether a patient is likely to suffer from CBZ toxicity. Hence, we planned to evaluate the use of genotyping and therapeutic drug monitoring (TDM) vs. only TDM in epileptic patients on CBZ as a strategy for risk minimization. Methods: This double-blind, randomized controlled trial included 60 epileptic patients taking carbamazepine, divided into two equal groups. One group’s carbamazepine dosing was guided by genotyping, while the other group’s doses were based solely on clinical judgment.Results: A total of 60 patients were enrolled in the study, in two arms, group A (genotyping and TDM both) and Group B (only TDM), each arm comprising 30 patients. Among the CYP3A5 metabolizer group, the frequency of expressors and non-expressors was (57%) and (43%), respectively. During follow-up visits, at one month, three cases of adverse drug reactions (ADRs) were reported. ADR count decreased to two cases during the three-month follow-up and further reduced to only one case of ADR at the 12-month assessment. It was found that there is no statistically significant association between CYP3A5 metabolizer and ADR occurrence.Conclusion: Adding genotyping to TDM did not significantly reduce the risk of carbamazepine toxicity. However, genotyping may still be useful for patients who exhibit symptoms of toxicity.https://dergipark.org.tr/en/download/article-file/4496181carbamazepinedrug monitoringdrug-related side effects and adverse reactionsgenetic polymorphismrisk evaluation and mitigation |
| spellingShingle | Hina Khimsuriya Sanchita Ambre Swati More Vinayak A Mahesh Belhekar A randomized controlled trial to evaluate genotyping and therapeutic drug monitoring vs. only therapeutic drug monitoring as a strategy for risk minimization in epileptic patients on carbamazepine therapy Recent Trends in Pharmacology carbamazepine drug monitoring drug-related side effects and adverse reactions genetic polymorphism risk evaluation and mitigation |
| title | A randomized controlled trial to evaluate genotyping and therapeutic drug monitoring vs. only therapeutic drug monitoring as a strategy for risk minimization in epileptic patients on carbamazepine therapy |
| title_full | A randomized controlled trial to evaluate genotyping and therapeutic drug monitoring vs. only therapeutic drug monitoring as a strategy for risk minimization in epileptic patients on carbamazepine therapy |
| title_fullStr | A randomized controlled trial to evaluate genotyping and therapeutic drug monitoring vs. only therapeutic drug monitoring as a strategy for risk minimization in epileptic patients on carbamazepine therapy |
| title_full_unstemmed | A randomized controlled trial to evaluate genotyping and therapeutic drug monitoring vs. only therapeutic drug monitoring as a strategy for risk minimization in epileptic patients on carbamazepine therapy |
| title_short | A randomized controlled trial to evaluate genotyping and therapeutic drug monitoring vs. only therapeutic drug monitoring as a strategy for risk minimization in epileptic patients on carbamazepine therapy |
| title_sort | randomized controlled trial to evaluate genotyping and therapeutic drug monitoring vs only therapeutic drug monitoring as a strategy for risk minimization in epileptic patients on carbamazepine therapy |
| topic | carbamazepine drug monitoring drug-related side effects and adverse reactions genetic polymorphism risk evaluation and mitigation |
| url | https://dergipark.org.tr/en/download/article-file/4496181 |
| work_keys_str_mv | AT hinakhimsuriya arandomizedcontrolledtrialtoevaluategenotypingandtherapeuticdrugmonitoringvsonlytherapeuticdrugmonitoringasastrategyforriskminimizationinepilepticpatientsoncarbamazepinetherapy AT sanchitaambre arandomizedcontrolledtrialtoevaluategenotypingandtherapeuticdrugmonitoringvsonlytherapeuticdrugmonitoringasastrategyforriskminimizationinepilepticpatientsoncarbamazepinetherapy AT swatimore arandomizedcontrolledtrialtoevaluategenotypingandtherapeuticdrugmonitoringvsonlytherapeuticdrugmonitoringasastrategyforriskminimizationinepilepticpatientsoncarbamazepinetherapy AT vinayaka arandomizedcontrolledtrialtoevaluategenotypingandtherapeuticdrugmonitoringvsonlytherapeuticdrugmonitoringasastrategyforriskminimizationinepilepticpatientsoncarbamazepinetherapy AT maheshbelhekar arandomizedcontrolledtrialtoevaluategenotypingandtherapeuticdrugmonitoringvsonlytherapeuticdrugmonitoringasastrategyforriskminimizationinepilepticpatientsoncarbamazepinetherapy AT hinakhimsuriya randomizedcontrolledtrialtoevaluategenotypingandtherapeuticdrugmonitoringvsonlytherapeuticdrugmonitoringasastrategyforriskminimizationinepilepticpatientsoncarbamazepinetherapy AT sanchitaambre randomizedcontrolledtrialtoevaluategenotypingandtherapeuticdrugmonitoringvsonlytherapeuticdrugmonitoringasastrategyforriskminimizationinepilepticpatientsoncarbamazepinetherapy AT swatimore randomizedcontrolledtrialtoevaluategenotypingandtherapeuticdrugmonitoringvsonlytherapeuticdrugmonitoringasastrategyforriskminimizationinepilepticpatientsoncarbamazepinetherapy AT vinayaka randomizedcontrolledtrialtoevaluategenotypingandtherapeuticdrugmonitoringvsonlytherapeuticdrugmonitoringasastrategyforriskminimizationinepilepticpatientsoncarbamazepinetherapy AT maheshbelhekar randomizedcontrolledtrialtoevaluategenotypingandtherapeuticdrugmonitoringvsonlytherapeuticdrugmonitoringasastrategyforriskminimizationinepilepticpatientsoncarbamazepinetherapy |